Edition:
United States

Corvus Pharmaceuticals Inc (CRVS.OQ)

CRVS.OQ on NASDAQ Stock Exchange Global Market

11.16USD
22 Jun 2018
Change (% chg)

$-1.34 (-10.72%)
Prev Close
$12.50
Open
$12.55
Day's High
$12.65
Day's Low
$10.51
Volume
685,333
Avg. Vol
42,014
52-wk High
$17.54
52-wk Low
$7.45

Chart for

About

Corvus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of immuno-oncology therapies. The Company is developing drugs and antibodies that block crucial immune checkpoints and reprogram immune T-cells. The Company has a pipeline of four immuno-onc... (more)

Overall

Beta: --
Market Cap(Mil.): $325.80
Shares Outstanding(Mil.): 29.19
Dividend: --
Yield (%): --

Financials

  CRVS.OQ Industry Sector
P/E (TTM): -- 248.83 34.14
EPS (TTM): -2.56 -- --
ROI: -41.87 -5.25 13.10
ROE: -42.22 -6.83 15.09

BRIEF-Corvus Pharmaceuticals Q1 Loss Per Share $0.63

* CORVUS PHARMACEUTICALS REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE

May 03 2018

BRIEF-Adams Street Partners Reports 15.5 Pct Stake In Corvus Pharma

* ADAMS STREET PARTNERS, LLC REPORTS 15.5 PERCENT STAKE IN CORVUS PHARMACEUTICALS INC AS OF MARCH 12, 2018 - SEC FILING‍​

Mar 21 2018

BRIEF-BVF Partners Reports 6.7 Pct Passive Stake In Corvus Pharmaceuticals

* BVF PARTNERS L.P. REPORTS 6.7 PERCENT PASSIVE STAKE IN CORVUS PHARMACEUTICALS INC AS OF MARCH 8, 2018 - SEC FILING‍​ Source text: (http://bit.ly/2G67UVx) Further company coverage:

Mar 19 2018

BRIEF-Corvus Pharma Announces Pricing Of Public Offering Of Common Stock

* CORVUS PHARMACEUTICALS ANNOUNCES PRICING OF PUBLIC OFFERING OF COMMON STOCK

Mar 08 2018

BRIEF-Corvus Pharma Announces Proposed Public Offering Of Common Stock

* CORVUS PHARMACEUTICALS ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK

Mar 07 2018

BRIEF-Corvus Pharmaceuticals Qtrly Net Loss Per Share $0.58

* CORVUS PHARMACEUTICALS REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE

Mar 01 2018

Earnings vs. Estimates